Expert Interview
A Second Opinion: Discussing the use of Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay
Ticker(s): APLS, ALPMFInstitution: Rush University & Illinois Retina Associates
- Assistant Professor of Ophthalmology at Rush University Medical Center & co-investigator on several clinical trials.
- Manages 20 patints a week with wAMD.
- Research interests include assessing the color performance of the NGENUITY 3D visualization system and meta-analyses of cytokines in various retinal diseases; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula.
Describe your background and practice setting
Added By: ben_adminHow many patients with GA do you manage? Has that number increased since the approval of Syfovre and Izervay?
Added By: ben_adminWhat GA patients are eligible for treatment?
Added By: ben_adminDo you have a preference between Izervay and Syfovre? If so, why?
Added By: ben_adminWhat percent of patients do you prescribe each medication to?
Added By: ben_adminWhich medication to you anticipate prescribing most often in the next 12 months?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
